NASDAQ · Biotechnology

EXOZ (EXOZ) Stock

$4.65 +1.09% NASDAQ: EXOZ Healthcare

Valuation

MetricValue
Price$4.65
Market Cap$43.16M
P/E Ratio-8.62
P/B Ratio26.57
P/S Ratio0.00
EPS (TTM)$-1.09
52-Week High$18.40
52-Week Low$4.55
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-300.00%
ROA-150.00%
ROCE-333.33%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.76
Current Ratio2.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-1.0M$-1.0M$-2.0M$-6.0M$-10.0M
Net Profit$-1.0M$-1.0M$-2.0M$-6.0M$-9.0M
EPS$-0.15$-0.17$-0.25$-0.72$-1.09
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$2.0M$3.0M$4.0M$13.0M$6.0M
Total Liabilities$1.0M$1.0M$4.0M$3.0M$3.0M
Cash$1.0M$1.0M$0$10.0M$3.0M
Borrowings$1.0M$1.0M$2.0M$1.0M$1.0M

Latest News

Q2 Virtual Investor Summit Presentations Now Available On Demand ACCESS Newswire · Jun 30, 2026 eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery ACCESS Newswire · Jun 24, 2026 Q2 Investor Summit Virtual Live Wednesday June 24 ACCESS Newswire · Jun 23, 2026 eXoZymes Inc. Announces Closing of $6 Million Public Offering ACCESS Newswire · Jun 17, 2026 EXoZymes Prices $5.3 Million Offering MT Newswires · Jun 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$-1.0M$-1.0M$-9.0M$-7.0M
Investing Cash Flow$-1.0M$0$-1.0M$-1.0M$0
Financing Cash Flow$0$0$1.0M$0$0
Net Cash Flow$0$0$0$10.0M$-7.0M
Free Cash Flow$-2.0M$-1.0M$-1.0M$-9.0M$-7.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-8.89%
Quick Ratio1.32
Interest Coverage—
Return 1Y-38.18%
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANEBAnebulo Pharmaceuticals, Inc. $0.34 +0.00% -1.73 $13.72M 0.00%
ATOS $2.36 -2.48% -1.23 $23.54M 0.00%
CGTX $0.89 +0.21% -3.94 $79.79M 0.00%
ESLAEstrella Immunopharma, Inc. $0.78 +0.06% -2.25 $33.59M 0.00%
GLSI $14.36 +0.84% -21.98 $210.78M 0.00%

About EXOZ

EXOZ is led by CEO Michael Heltzen, employs 31 people, headquartered in US, publicly traded since 2024.

EXOZ stock trades at $4.65 with a market capitalization of $43.16M. The stock is valued at a price-to-earnings (P/E) ratio of -8.62, price-to-book of 26.57, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $4.55 and $18.40, and currently trades 74.7% below its 52-week high.

On profitability, EXOZ generates a return on equity (ROE) of -300.00%, return on capital employed of -333.33%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides